|Bid||9.10 x 100000|
|Ask||9.35 x 100000|
|Day's Range||9.05 - 9.05|
|52 Week Range||3.41 - 11.67|
|Beta (3Y Monthly)||0.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead ...
Shares of Karyopharm Therapeutics reversed an early pop Friday after gaining FDA approval for a drug called Xpovio as a multiple myeloma treatment. Shares of biotech DBV also soared higher.
The FDA's decision to approve Xpovio was based on the overall response rate of 25.3% in the 83-patient subgroup of the Phase 2b STORM trial, White said in a Friday note. H.C. Wainwright estimates the sales potential in the penta-refractory setting to be $5.5 million in 2019, rising to $123.8 million in 2026.
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
Wednesday, the stock of Karyopharm Therapeutics Inc. advanced more than 35% in trading. The trigger for the rally was U.S. Food and Drug Administration (FDA) approval of its compound Xpovio, also known as selinexor, for the treatment of penta-refractory multiple myeloma. It was an unexpected victory for Karyopharm and its shareholders considering a recent 8-5 vote by an FDA advisory committee recommending that approval of Xpovio be delayed until additional Phase 3 data was disclosed later this year.
The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer. "Sadly, often over time, patients can exhaust all available treatments and still see their disease progress," said Richard Pazdur, director of the FDA's Oncology Center of Excellence. Karyopharm said it expects Xpovio to become commercially available in the United States by July 10.
On a per-share basis, the Newton, Massachusetts-based company said it had a loss of $1.09. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...
As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.
Billionaire investor Steven Cohen (Trades, Portfolio), who heads up hedge fund Point72 Asset Management, disclosed he upped his stake in Karyopharm Therapeutics Inc. (KPTI) on Feb. 22. Warning! GuruFocus has detected 5 Warning Signs with KPTI.
Wedbush analyst David Nierengarten maintained an Outperform rating on KaryoPharm shares and lowered the price target from $14 to $6. The FDA panel's 8-5 vote in favor of delaying selinexor approval until the results of the Phase 3 BOSTON trial are out suggests that the key concerns around safety, dose reduction and study design underlined in the briefing documents prevail, Wedbush's Nierengarten said in a Wednesday note.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 26) AstraZeneca plc (NYSE: AZN )(announced positive results ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
Karyopharm submitted a NDA for a combination of selinexor and dexamethasone that is being evaluated for penta-refractory multiple myeloma. The NDA was submitted based on Part 2 of the Phase 2b trial dubbed STORM — a multicenter, open-label, single-arm trial.
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 10.23% and -80.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?